Surgery for osteosarcoma with isolated pulmonary metastases: A SEER-based analysis

IF 3.5 2区医学 Q2 Medicine

Journal of Bone Oncology Pub Date : 2025-07-28 DOI:10.1016/j.jbo.2025.100706

Sheng-Fen Liu

{"title":"Surgery for osteosarcoma with isolated pulmonary metastases: A SEER-based analysis","authors":"Sheng-Fen Liu","doi":"10.1016/j.jbo.2025.100706","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Osteosarcoma frequently metastasizes to the lungs. The role of surgical intervention in patients with isolated pulmonary metastases and early-stage primary tumors (T1-T2) remains unclear.</div></div><div><h3>Methods</h3><div>Data from the SEER database were used to identify osteosarcoma patients diagnosed with T1-T2 stage disease and isolated lung metastases. Patients were categorized based on whether they underwent surgery for the primary tumor. Propensity score matching (PSM) was applied to reduce baseline differences.</div></div><div><h3>Results</h3><div>Before PSM, surgery was associated with significantly improved overall survival (OS) (median OS: 19.0 vs 7.0 months, P < 0.001). After PSM, a trend toward better OS persisted (median OS: 13.0 vs 9.0 months, P = 0.253), though not statistically significant. Surgery was also associated with lower cancer-related death rates both before and after PSM.</div></div><div><h3>Conclusions</h3><div>Surgical resection of the primary tumor may confer a survival benefit in T1-T2 osteosarcoma patients with isolated pulmonary metastases. These findings support the continued evaluation of surgical strategies in metastatic osteosarcoma and underscore the need for prospective validation.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100706"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212137425000478","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Osteosarcoma frequently metastasizes to the lungs. The role of surgical intervention in patients with isolated pulmonary metastases and early-stage primary tumors (T1-T2) remains unclear.

Methods

Data from the SEER database were used to identify osteosarcoma patients diagnosed with T1-T2 stage disease and isolated lung metastases. Patients were categorized based on whether they underwent surgery for the primary tumor. Propensity score matching (PSM) was applied to reduce baseline differences.

Results

Before PSM, surgery was associated with significantly improved overall survival (OS) (median OS: 19.0 vs 7.0 months, P < 0.001). After PSM, a trend toward better OS persisted (median OS: 13.0 vs 9.0 months, P = 0.253), though not statistically significant. Surgery was also associated with lower cancer-related death rates both before and after PSM.

Conclusions

Surgical resection of the primary tumor may confer a survival benefit in T1-T2 osteosarcoma patients with isolated pulmonary metastases. These findings support the continued evaluation of surgical strategies in metastatic osteosarcoma and underscore the need for prospective validation.

查看原文本刊更多论文

骨肉瘤伴孤立性肺转移的手术治疗：基于seer的分析

背景：骨肉瘤经常转移到肺部。手术干预在孤立性肺转移和早期原发性肿瘤（T1-T2）患者中的作用尚不清楚。方法采用SEER数据库中的数据，识别诊断为T1-T2期疾病和分离肺转移的骨肉瘤患者。患者根据是否接受原发肿瘤手术进行分类。倾向评分匹配（PSM）用于减少基线差异。结果在PSM之前，手术与总生存期（OS）的显著改善相关（中位OS: 19.0 vs 7.0个月，P < 0.001）。PSM后，OS改善的趋势持续存在（中位OS: 13.0 vs 9.0个月，P = 0.253），尽管没有统计学意义。手术也与PSM前后较低的癌症相关死亡率相关。结论手术切除原发肿瘤可能会提高T1-T2骨肉瘤患者的生存率。这些发现支持了转移性骨肉瘤手术策略的持续评估，并强调了前瞻性验证的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Bone Oncology ONCOLOGY-

CiteScore

7.20

自引率

2.90%

发文量

审稿时长

34 days

期刊介绍： The Journal of Bone Oncology is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to bone and cancer. As the first journal dedicated to cancer induced bone diseases, JBO welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject. The areas covered by the journal include: Bone metastases (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment) Preclinical models of metastasis Bone microenvironment in cancer (stem cell, bone cell and cancer interactions) Bone targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics) Cancer treatment induced bone loss (epidemiology, pathophysiology, prevention and management) Bone imaging (clinical and animal, skeletal interventional radiology) Bone biomarkers (clinical and translational applications) Radiotherapy and radio-isotopes Skeletal complications Bone pain (mechanisms and management) Orthopaedic cancer surgery Primary bone tumours Clinical guidelines Multidisciplinary care Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour.